NEW YORK, April 10, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc. ("Synergy" or the "Company") (NASDAQ:SGYP) and certain of its officers, on behalf of shareholders who purchased Synergy securities during the period between September 5, 2017 and November 14, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sgyp.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On September 5, 2017, Synergy revealed that it had closed on a "non-dilutive" $300 million loan from CRG Partners III L.P., which would be available to the Company "when needed" to fund its operations through 2019. On November 14, 2017, Synergy divulged the loan agreement terms, that was not previously disclosed, prevented the Company from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash, and therefore, Synergy was conducting a secondary offering of its shares. Consequently, contrary to Defendants' previous statements at the beginning of the Class Period, the loan was not available to Synergy "when needed," would result in dilution of the outstanding shares, and would not be sufficient to fund operations through 2019, without dilution. Following the news, Synergy stock dropped as low as $1.68 per share.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sgyp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Telegram Restored on Apple App Store After Temporary Removal
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 



